137 related articles for article (PubMed ID: 8137462)
1. Uptake of doxorubicin from loaded nanoparticles in multidrug-resistant leukemic murine cells.
Colin de Verdière A; Dubernet C; Nemati F; Poupon MF; Puisieux F; Couvreur P
Cancer Chemother Pharmacol; 1994; 33(6):504-8. PubMed ID: 8137462
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance.
Cuvier C; Roblot-Treupel L; Millot JM; Lizard G; Chevillard S; Manfait M; Couvreur P; Poupon MF
Biochem Pharmacol; 1992 Aug; 44(3):509-17. PubMed ID: 1354963
[TBL] [Abstract][Full Text] [Related]
3. Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: towards a mechanism of action.
de Verdière AC; Dubernet C; Némati F; Soma E; Appel M; Ferté J; Bernard S; Puisieux F; Couvreur P
Br J Cancer; 1997; 76(2):198-205. PubMed ID: 9231919
[TBL] [Abstract][Full Text] [Related]
4. Anthracycline resistance in murine leukemic P388 cells. Role of drug efflux and glutathione related enzymes.
Nair S; Singh SV; Samy TS; Krishan A
Biochem Pharmacol; 1990 Feb; 39(4):723-8. PubMed ID: 2306280
[TBL] [Abstract][Full Text] [Related]
5. Medicarpin and millepurpan, two flavonoids isolated from Medicago sativa, induce apoptosis and overcome multidrug resistance in leukemia P388 cells.
Gatouillat G; Magid AA; Bertin E; El btaouri H; Morjani H; Lavaud C; Madoulet C
Phytomedicine; 2015 Dec; 22(13):1186-94. PubMed ID: 26598918
[TBL] [Abstract][Full Text] [Related]
6. Modulation of subcellular distribution of doxorubicin in multidrug-resistant P388/ADR mouse leukemia cells by the chemosensitizer ((2-isopropyl-1-(4-[3-N-methyl-N-(3,4-dimethoxy-beta- phenethyl)amino]propyloxy)-benzenesulfonyl))indolizine.
Jaffrézou JP; Levade T; Chatelain P; Laurent G
Cancer Res; 1992 Dec; 52(23):6440-6. PubMed ID: 1423291
[TBL] [Abstract][Full Text] [Related]
7. Electrophoretic mobility studies on doxorubicin-resistant and -sensitive murine P388 leukemic cells.
Nair S; Horton A; Leif RC; Krishan A
Cytometry; 1988 May; 9(3):232-7. PubMed ID: 3163971
[TBL] [Abstract][Full Text] [Related]
8. Ability of doxorubicin-loaded nanoparticles to overcome multidrug resistance of tumor cells after their capture by macrophages.
Soma CE; Dubernet C; Barratt G; Nemati F; Appel M; Benita S; Couvreur P
Pharm Res; 1999 Nov; 16(11):1710-6. PubMed ID: 10571276
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of pirarubicin cytotoxicity by dipyridamole in doxorubicin-resistant mouse P388 leukemia cells.
Furusawa S; Fujimura T; Kawauchi H; Sasaki K; Takayanagi Y
Res Commun Chem Pathol Pharmacol; 1991 Mar; 71(3):321-36. PubMed ID: 2047575
[TBL] [Abstract][Full Text] [Related]
10. [Modulation of anthracycline resistance by reserpine in P388 leukemia cells].
Shibata H; Furusawa S; Kawauchi H; Sasaki K; Takayanagi Y
Nihon Yakurigaku Zasshi; 1991 Jul; 98(1):1-6. PubMed ID: 1889760
[TBL] [Abstract][Full Text] [Related]
11. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors.
Krishna R; Mayer LD
Cancer Res; 1997 Dec; 57(23):5246-53. PubMed ID: 9393743
[TBL] [Abstract][Full Text] [Related]
12. Effects of xanthine derivatives on the influx and efflux of doxorubicin in P388 and DOX-resistant P388 leukemia cells.
Sadzuka Y; Egawa Y; Sawanishi H; Miyamoto K; Sonobe T
Toxicol Lett; 2002 Sep; 135(1-2):137-44. PubMed ID: 12243872
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy of a phenothiazine and a bisquinaldinium calmodulin antagonist against multidrug-resistant P388 cell lines.
Hait WN; Pierson NR
Cancer Res; 1990 Feb; 50(4):1165-9. PubMed ID: 2297765
[TBL] [Abstract][Full Text] [Related]
14. Pulsed exposure of SDZ PSC 833 to multidrug resistant P388/ADR and MCF7/ADR cells in the absence of anticancer drugs can fully restore sensitivity to doxorubicin.
Krishna R; de Jong G; Mayer LD
Anticancer Res; 1997; 17(5A):3329-34. PubMed ID: 9413167
[TBL] [Abstract][Full Text] [Related]
15. Mesoporous silica nanoparticles loading doxorubicin reverse multidrug resistance: performance and mechanism.
Shen J; He Q; Gao Y; Shi J; Li Y
Nanoscale; 2011 Oct; 3(10):4314-22. PubMed ID: 21892492
[TBL] [Abstract][Full Text] [Related]
16. Exploring multidrug resistance using rhodamine 123.
Kessel D
Cancer Commun; 1989; 1(3):145-9. PubMed ID: 2639727
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin and resveratrol co-delivery nanoparticle to overcome doxorubicin resistance.
Zhao Y; Huan ML; Liu M; Cheng Y; Sun Y; Cui H; Liu DZ; Mei QB; Zhou SY
Sci Rep; 2016 Oct; 6():35267. PubMed ID: 27731405
[TBL] [Abstract][Full Text] [Related]
18. Circumvention of adriamycin resistance: effect of 2-methyl-1,4-naphthoquinone (vitamin K3) on drug cytotoxicity in sensitive and MDR P388 leukemia cells.
Parekh HK; Mansuri-Torshizi H; Srivastava TS; Chitnis MP
Cancer Lett; 1992 Jan; 61(2):147-56. PubMed ID: 1730138
[TBL] [Abstract][Full Text] [Related]
19. A self-assembled polyjuglanin nanoparticle loaded with doxorubicin and anti-Kras siRNA for attenuating multidrug resistance in human lung cancer.
Wen ZM; Jie J; Zhang Y; Liu H; Peng LP
Biochem Biophys Res Commun; 2017 Dec; 493(4):1430-1437. PubMed ID: 28958938
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy with cytochalasin congeners in vitro and in vivo against murine models.
Trendowski M; Mitchell JM; Corsette CM; Acquafondata C; Fondy TP
Invest New Drugs; 2015 Apr; 33(2):290-9. PubMed ID: 25563824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
